A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer

2025/02/18 by Jennifer J. Knox, Mairéad G. McNamara, I. Bazin +30 · 1 voice
Medicine · #Cholangiocarcinoma and Gallbladder Cancer Studies #Gallbladder and Bile Duct Disorders #Pancreatic and Hepatic Oncology Research

paper · doi:10.1016/j.jhep.2025.01.040

openalex publication_date 2025/02/18 · crossref created 2025/02/18 · openalex created_date 2025/02/19 · crossref issued 2025/08/01 · crossref published 2025/08/01 · crossref published-print 2025/08/01 · crossref deposited 2026/03/12 · crossref indexed 2026/07/20 · openalex updated_date 2026/07/28

Citations

• Global cancer statistics, 2012

Discussions

• A phase III randomised study of first-line NUC-1031/ cisplatin vs GemCis in advanced biliary tract cancer @JHepatology doi.org/10.1016/j.jh... 👉mOS 9.2 vs 12.6 mo 👉Early toxicity & liver injury in [bsky, 2 points, 0 comments]